| Bioactivity | Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling[1]. |
| In Vivo | PRN473 (20 mg/kg) significantly reduces intravascular crawling and neutrophil recruitment into inflamed tissue in a model of sterile liver injury, down to levels seen in Btk-deficient animals[1]. |
| Name | Atuzabrutinib |
| CAS | 1581714-49-9 |
| Formula | C30H30FN7O2 |
| Molar Mass | 539.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Herter JM, et al. PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling. Br J Pharmacol. 2018;175(3):429-439. |
Atuzabrutinib
CAS: 1581714-49-9 F: C30H30FN7O2 W: 539.60
Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuz
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.